Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Bank of America Corp DE Sells 155,174 Shares of Nektar Therapeutics (NASDAQ:NKTR)
08:42am, Thursday, 16'th Apr 2020
Bank of America Corp DE lowered its position in Nektar Therapeutics (NASDAQ:NKTR) by 47.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange
RemeGen candidate Fast Track'd for lupus
03:13pm, Wednesday, 15'th Apr 2020
The FDA has signed off on Fast Track status for Yantai, China-based RemeGen's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE).RC18 (telitacicept) is a recombinant TACI-F
NYC reaches deal on seeking board, CEO diversity at 13 companies
07:11pm, Tuesday, 14'th Apr 2020Urban Gardening: Machen Sie die Welt ein wenig grüner - Blick
02:34pm, Monday, 13'th Apr 2020
«Urban Gardening» nennt sich der erdige Trend der letzten Jahre, der unentwegt anhält. In der jetzigen Zeit, wo man den ganzen Tag zu Hause bleiben muss, der richtige Zeitpunkt für dieses Projekt.
Nektar Therapeutics (NASDAQ:NKTR) Expected to Post Quarterly Sales of $45.00 Million
08:44am, Monday, 13'th Apr 2020
Brokerages forecast that Nektar Therapeutics (NASDAQ:NKTR) will post $45.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estima
Mizuho Securities Thinks Xeris Pharmaceuticals' Stock is Going to Recover
02:00am, Monday, 13'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) yesterday and set a price target of $18.00. The company's
Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover
02:00am, Monday, 13'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) yesterday and set a
Nektar Therapeutics (NASDAQ:NKTR) Expected to Post Earnings of -$0.75 Per Share
09:34am, Saturday, 11'th Apr 2020
Wall Street brokerages forecast that Nektar Therapeutics (NASDAQ:NKTR) will post earnings per share (EPS) of ($0.75) for the current quarter, Zacks reports. Seven analysts have provided estimates for
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
10:08pm, Thursday, 09'th Apr 2020
Sean McCarthy, president and CEO of CytomX Therapeutics Inc.
ReAlta Life Sciences, Inc., a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform to address life-threatening medical needs, today announced tha
Nektar Therapeutics (NASDAQ:NKTR) Stock Holdings Increased by Macquarie Group Ltd.
11:48am, Thursday, 09'th Apr 2020
Macquarie Group Ltd. grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 17
Ladenburg Thalmann Financial Services Inc. Increases Stock Position in Nektar Therapeutics (NASDAQ:NKTR)
10:48am, Thursday, 09'th Apr 2020
Ladenburg Thalmann Financial Services Inc. grew its position in Nektar Therapeutics (NASDAQ:NKTR) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Secu
Worldwide Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com
10:40am, Thursday, 09'th Apr 2020
The "Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
Nektar Therapeutics (NASDAQ:NKTR) Shares Sold by Geode Capital Management LLC
09:42am, Thursday, 09'th Apr 2020
Geode Capital Management LLC trimmed its position in Nektar Therapeutics (NASDAQ:NKTR) by 27.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities an
Alliancebernstein L.P. Raises Holdings in Nektar Therapeutics (NASDAQ:NKTR)
09:08am, Wednesday, 08'th Apr 2020
Alliancebernstein L.P. increased its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 14.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 307,895 shares of t
